Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/114176
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pedrosa, Ana Realista | - |
dc.contributor.author | Martins, Diana Cruz | - |
dc.contributor.author | Rizzo, Manfredi | - |
dc.contributor.author | Silva-Nunes, José | - |
dc.date.accessioned | 2024-03-25T12:45:32Z | - |
dc.date.available | 2024-03-25T12:45:32Z | - |
dc.date.issued | 2023-02 | - |
dc.identifier.issn | 10568727 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/114176 | - |
dc.description.abstract | SARS-CoV-2 infection has been a major threat to human health and a huge challenge to Medicine. In only two years, COVID-19 affected >350 million people, causing >5.6 million deaths. Chronic inflammatory states, such as diabetes or obesity, are known risk factors for COVID-19 poorest outcomes, with higher risk for disease severity and greater mortality. Metformin remains on the first line of the management of hyperglycemia in type 2 diabetes. Through its anti-inflammatory and immunomodulatory mechanisms, metformin appears as an opportunity to control the dysregulated cytokine storm secondary to SARS-CoV-2 infection. Recent studies point towards a potential protective role of metformin in the course of COVID-19, showing that current or previous treatment with metformin associates with better outcomes. | pt |
dc.language.iso | eng | pt |
dc.publisher | Elsevier | pt |
dc.rights | openAccess | pt |
dc.subject | Metformin | pt |
dc.subject | SARS-CoV-2 | pt |
dc.subject | COVID-19 | pt |
dc.subject | Diabetes | pt |
dc.subject | Mortality | pt |
dc.subject | Severity | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | SARS-CoV-2 | pt |
dc.subject.mesh | Inflammation | pt |
dc.subject.mesh | COVID-19 | pt |
dc.subject.mesh | Metformin | pt |
dc.subject.mesh | Diabetes Mellitus, Type 2 | pt |
dc.title | Metformin in SARS-CoV-2 infection: A hidden path - from altered inflammation to reduced mortality. A review from the literature | pt |
dc.type | article | - |
degois.publication.firstPage | 108391 | pt |
degois.publication.issue | 2 | pt |
degois.publication.title | Journal of Diabetes and its Complications | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1016/j.jdiacomp.2022.108391 | pt |
degois.publication.volume | 37 | pt |
dc.date.embargo | 2023-02-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | open | - |
item.fulltext | Com Texto completo | - |
item.cerifentitytype | Publications | - |
item.openairetype | article | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Metformin in SARS-CoV-2 infection A hidden path – from altered inflammation to reduced mortality. A review from the literature.pdf | 4.46 MB | Adobe PDF | View/Open |
Page view(s)
138
checked on Aug 14, 2024
Download(s)
120
checked on Aug 14, 2024
Google ScholarTM
Check
Altmetric
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.